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Abstract
Background: Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) syndromes are associated to germline TP53 mutations,
and are characterized by the development of central nervous system tumors, sarcomas, adrenocortical carcinomas,
and other early-onset tumors. Due to the high frequency of breast cancer in LFS/LFL families, these syndromes
clinically overlap with hereditary breast cancer (HBC). Germline point mutations in BRCA1, BRCA2, and TP53 genes
are associated with high risk of breast cancer. Large rearrangements involving these genes are also implicated in
the HBC phenotype.
Methods: We have screened DNA copy number changes by MLPA on BRCA1, BRCA2, and TP53 genes in 23 breast
cancer patients with a clinical diagnosis consistent with LFS/LFL; most of these families also met the clinical criteria
for other HBC syndromes.
Results: We found no DNA copy number alterations in the BRCA2 and TP53 genes, but we detected in one patient
a 36.4 Kb BRCA1 microdeletion, confirmed and further mapped by array-CGH, encompassing exons 9–19.
Breakpoints sequencing analysis suggests that this rearrangement was mediated by flanking Alu sequences.
Conclusion: This is the first description of a germline intragenic BRCA1 deletion in a breast cancer patient with a
family history consistent with both LFL and HBC syndromes. Our results show that large rearrangements in these
known cancer predisposition genes occur, but are not a frequent cause of cancer susceptibility.
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Background
Germline mutations of the tumor suppressor gene TP53
account for more than half of the families with classic
Li-Fraumeni syndrome (LFS) [1], which is an inherited
condition characterized by the development of sarcomas
and other early-onset tumors, including breast cancer
[2,3]. Families presenting incomplete features of LFS are
referred as having Li-Fraumeni-like syndrome (LFL). De-
pending on the criteria adopted to classify the cancer
phenotype in a given family, up to 22% of LFL pedigrees
have detectable TP53 mutations [4-6]. Several cancer
predisposition syndromes that involve breast cancer have
been described to date, and include, in addition to LFS/
LFL, the hereditary breast and ovarian cancer (HBOC),
hereditary diffuse gastric cancer, and the Cowden and
Peutz-Jeghers syndromes [7]. Due to the high frequency
of breast and other cancers in LFS/LFL individuals, there
may be an overlap of phenotypes, and often some fam-
ilies fulfill genetic testing criteria for more than one her-
editary breast cancer syndrome [1,8,9].
Several studies have investigated the frequency of
BRCA1/BRCA2 and TP53 germline mutations in fam-
ilies with multiple early-onset breast cancers [6,8,10,11].
Approximately 5-10% of breast cancer is estimated to
result from dominant mutations in known single genes
[12-14], particularly in the BRCA1 or BRCA2 genes. Germ-
line TP53 mutations have been considered to be respon-
sible for only a small fraction of the hereditary breast
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cancer cases overall [15], and have mostly been described
in families with the other core-cancers of LFS/LFL [1,8,9].
Germline mutations of the BRCA2 gene have been
described in families presenting both breast cancer and sar-
comas, suggesting that BRCA2 mutations account for a
proportion of LFS/LFL families negative for TP53 muta-
tions [16,17]. As far as we are aware, germline BRCA1
mutations have not been detected in LFS/LFL kindreds,
not even among families presenting a complex cancer his-
tory consistent both with LFL and other syndromes that
constitute the HBC phenotype [6,8,11,18].
All known breast cancer susceptibility genes present
germline point mutations in only approximately 20-25%
of the cases fulfilling the criteria for genetic testing [12].
Gene rearrangements can contribute to disease through
different mechanisms, resulting in either imbalance of
gene dosage or gene disruption, and they are not usually
detected by routine molecular diagnostic methods such
as gene sequencing. In particular, large rearrangements,
most often deletions, have been reported as a cause of
cancer susceptibility, occurring in at least 30% of highly
penetrant Mendelian cancer-predisposing genes [19].
BRCA1 germline rearrangements have been implicated
in up to 30% of HBC families in certain populations
[19-23]. The aim of the present study was to deter-
mine the frequency of germline copy number changes of
TP53, BRCA1, and BRCA2 genes in breast cancer
patients with clinical diagnosis of Li-Fraumeni or Li-
Fraumeni-like syndrome, and without detectable germ-
line TP53 point mutations.
Results
All studied patients were females affected by breast can-
cer, two of them with bilateral disease, and 11 (45.8%)
with more than one primary tumor. The average age at
breast cancer diagnosis was 41 years (SD: 11.5; range:
26–61 years). Nineteen of the 23 families met genetic
testing criteria for both LFL and another hereditary
breast cancer syndrome (Table 1); two families met cri-
teria for both classic LFS and another hereditary breast
cancer syndrome, and two fulfill only the criteria for LFL.
In the MLPA analysis none of the patients showed TP53,
or BRCA2 deletions or duplications. We identified a single
patient carrying a heterozygous intragenic BRCA1 micro-
deletion (Y54). Analysis using two different sets of MLPA
probes (kits P087 and P002) and array-CGH allowed con-
firming a deletion that spanned from exon 9 to 19 (Figure 1
depicts the chromosome 17q21.31 array-CGH profile of
Table 1 Characteristics of the probands: clinical phenotype, type of tumor and age of diagnosis (years)
Individual Code Classification Breast tumor (age at diagnosis) Other tumors (age at diagnosis)
Y6T000 Birch breast (79) Lymphoma (73), skin (81)
Y29T000 Birch/HBC breast (26) Osteosarcoma (19), soft tissue sarcoma (23), head/neck (24)
Y36T000 Birch/HBC breast (44)
Y41T000 Chompret/HBC breast (28) Osteosarcoma (8)
Y51T000 Eeles1 breast (53)
Y54T000 Eeles1/HBC breast (41) Endometrium (44)
Y83T000 Chompret/HBC breast (45) Soft tissue sarcoma (21)
Y93T000 LFS/HBC breast (42)
Y95T000 Eeles2/HBC breast (36)
Y101T000 Eeles1/HBC breast (48) Thyroid (52)
Y110T000 Eeles1/HBC breast (36)
Y112T000 Chompret/HBOC breast (34)
Y115T000 Chompret/HBC breast (36)
Y116T000 Eeles2/HBC breast (48)
Y117T000 Eeles1/HBC breast (44)
Y122T000 Eeles1/HBC breast (61) Colorectal cancer(68)
Y123T000 Eeles1/HBC breast bilateral (37)
Y126T000 Chompret/HBC breast (39) Lymphoma (23), skin (40)
Y135T000 Eeles1/HBC breast (30)
Y143T000 Eeles1/HBC breast (42)
Y145T000 Chompret/HBC breast, bilateral (36; 36)
Y147T000 Chompret/HBC breast (35) Melanoma (36)
Y152T000 LFS/HBC breast (38) Skin (36)
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the patient, indicating the position of the BRCA1 microde-
letion). We tested two non-affected relatives of patient Y54
(III.13 and III.16) and found that one of them carries the
BRCA1 deletion (III.16). Unfortunately, affected relatives of
the patient Y54 could not be investigated for the presence
of the BRCA1 deletion either because they were deceased
or were not available.
The DNA fragment containing the rearrangement
breakpoints was sequenced and the results showed that
the deletion starts at intron 8 and ends at intron 19 of
the BRCA1 gene, resulting in a deletion-block identified
as: g.29197_65577del36381 (Figure 2). Detailed in silico
assessment of the genomic sequences surrounding the
breakpoints showed that consensus Alu sequences
flanked them.
Clinically, this family fulfilled genetic testing criteria for
both hereditary breast and ovarian cancer (HBOC) and
LFL (Eeles 1 criteria) syndromes; the cancer family history
was significant for the presence of two individuals with
multiple primary tumors, including the proband (Figure 3).
Discussion
In families with a breast cancer history that suggests the
involvement of high risk genes such as TP53, BRCA1
Figure 1 Mapping of the intragenic BRCA1 deletion detected in a patient with multiple primary tumors and a cancer family history
fulfilling criteria for TP53 and BRCA testing. In the upper panel, the array-CGH profile of a region at chromosome band 17q21.31, showing a
heterozygous loss in copy number (red bar) of a genomic segment (image adapted from the Genomic Workbench software, Agilent
Technologies). The lower panel displays the deleted segment (solid black bar) in the context of the genomic region, encompassing exons 9–19
of the BRCA1 gene according to the analysis of breakpoint sequencing data (image adapted from UCSC Genome Bioinformatics, http://genome.
ucsc.edu, Build 37.1).
Figure 2 Breakpoint sequencing analysis. Eletropherogram showing the g.29197_65577del36381 mutation in the BRCA1 sequence; the intron
8 sequence is followed by intron 19 sequence. The blue arrow represents the inferred breakpoint.
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and BRCA2, a more extensive analysis of these genes
should be considered. In this study we have screened
three major breast cancer predisposition genes for copy
number changes in a group of 23 breast cancer patients
with the clinical diagnosis of LFS/LFL who had no germ-
line TP53 point mutations.
We did not identify large rearrangements encompass-
ing TP53, which is in line with previous reports of low
prevalence of such alterations, encountered in less than
5% of LFS/LFL families [24,25].
Similarly, large rearrangements in other breast cancer
predisposition genes seem to be infrequent. A few
BRCA2 deletions have been previously reported in fam-
ilies with male breast cancer [26], and contribute to in-
activate this gene in breast cancer families [21,27].
Rearrangements affecting the BRCA2 gene have also
been reported in breast/sarcoma families, causing a Li–
Fraumeni type of cancer pattern [16]. Although none of
the families included in this study had male breast can-
cer cases, nine of them had a breast cancer/sarcoma
phenotype; however, no BRCA2 rearrangements were
identified, which may be related to the relatively small
sample size.
BRCA1 rearrangements, on the other hand, are more
prevalent mostly due to the high density of Alu elements
throughout the BRCA1 locus [28]. A large study by
Walsh et al (2006) [11] suggested that the mutation
spectra of BRCA1/BRCA2 includes several genomic
rearrangements, and those alterations seem to be par-
ticularly frequent in certain populations (due to founder
effect), and in families presenting individuals with mul-
tiple primary tumors [20,21,29,30]. Indeed, the “multiple
primary tumors” phenotype was observed in the BRCA1
rearrangement-positive family identified in our series.
Interestingly, the BRCA1 microdeletion identified here
appears to be the same as the one identified in a breast
cancer Italian patient [20]. Our patient is originally from
southern Brazil, and since Italians have strongly contrib-
uted to the ethnic make-up of southern Brazilian popu-
lation [31] it is possible that the Brazilian and the Italian
patients have a common ancestry. Considering that we
could not establish the parental origin of the rearrange-
ment, this large genomic deletion may represent a breast
cancer susceptibility allele rather than a more general
cancer predisposition factor.
This study contributes to the understanding of the eti-
ology of cancer susceptibility in Li-Fraumeni (LFS) and
Li-Fraumeni-like (LFL) families, and their possible rela-
tion to large genomic rearrangements in high risk breast
cancer susceptibility genes.
Conclusion
In patients with a cancer family history consistent with
genetic testing criteria for multiple breast cancer syn-
dromes, a comprehensive investigation, including full
gene sequencing and rearrangement screening of mul-
tiple loci may be necessary to determine the precise mo-
lecular mechanisms underlying the disease. However, as
illustrated with this study, in many families with cancer
histories clearly indicative of hereditary cancer predis-
position, the disease-causing molecular mechanisms re-
main elusive. Thus, despite the availability of extensive
genotyping and sequencing approaches, determination
of the precise pathogenic mechanisms of hereditary can-
cer in many cases is still a significant challenge.
Methods
Patients
The research protocol was approved by the institutional
ethics committees of the participating Institutions
(Protocol numbers 1175/08 and GPPG-HCPA 04–081),
and recruitment of patients was done after signature of
informed consent. DNA samples from 23 patients were
obtained from peripheral blood; sample quality was
Figure 3 Pedigree of the family with a large BRCA1 rearrangement. Type of cancer is indicated under the subjects and the age of diagnosis
is shown in brackets.
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assessed using Nanodrop and molecular weight was
checked by electrophoresis in 0.8% agarose gels. TP53
mutation testing was previously performed by direct se-
quencing of exons 2–11, using the protocols published
in http://www-p53.iarc.fr/p53sequencing.html [24].
Family history was recorded in detailed pedigrees with
information traced as far backwards and laterally as pos-
sible, extending to paternal lines and including a mini-
mum of three generations. Confirmation of the family
history of cancer was attempted in all cases and path-
ology reports, medical records and/or death certificates
were obtained whenever possible.
We selected 23 breast cancer patients with an indica-
tion for TP53 mutation testing due to a Li-Fraumeni or
Li-Fraumeni-like phenotype according to the classical
criteria [32] or at least one of the LFL definitions:
Chompret, Birch or Eeles [4,33-35]. In all families, TP53
mutation testing was negative [36]. Additionally, some of
these families also fulfilled mutation testing criteria for
other hereditary breast cancer syndromes, as described
in the NCCN Practice Guidelines in Oncology –
v.1.2010 [37].
Clinical features of the 23 probands are summarized in
Table 1.
Multiplex ligation probe amplification (MLPA)
Deletions and duplications affecting all coding exons of
the TP53 gene (12 probes) were investigated by MLPA
[38](MRC-Holland, Amsterdam, The Netherlands, kit
P056). MLPA experiments were performed in duplicates
for each patient sample, with simultaneous analysis of
DNA samples from two healthy individuals from the
general population (negative controls), and two patients
carrying previously characterized germlineTP53 rearran-
gements (positive controls: a Li-Fraumeni patient with
an intragenic TP53 deletion [39]; and a patient harboring
a large 17p13 duplication from our in-house database).
Deletions and duplications affecting BRCA1 and BRCA2
exons were also investigated by MLPA (MRC-Holland,
Amsterdam, The Netherlands, kits P087 and P045, re-
spectively; kit P002 was also used for confirmatory ana-
lysis of one detected BRCA1 microdeletion); duplicated
experiments were performed simultaneously in samples
from patients, two healthy individuals, and samples pre-
viously identified as carrying large duplications encom-
passing the BRCA1 and BRCA2 genes (positive controls;
patients from our in-house database).
The PCR-amplified fragments were separated by capil-
lary electrophoresis on an ABI 3130 XL genetic analyzer
(Applied Biosystems, Foster City, California), and ana-
lyzed using the Coffalyser software (MRC Holland). We
performed direct normalization with control probes as
normalization factor, using the median of all imported
samples, and two standard deviations. Values >1.3 were
considered as possible duplications, and deletions were
considered for probes exhibiting values < 0.7. Using this
analysis, alterations present in all positive controls were
detected.
Comparative genomic hybridization on microarrays
(array-CGH)
Array-CGH analysis was performed as previously
described [40] to confirm an intragenic BRCA1 deletion
detected by MLPA in one patient (Y54). We used a
whole-genome 180 K platform (Agilent Technologies),
according to the manufacturer’s instructions; a gain or
loss in copy number was considered when the log2 ratio
of the Cy3/Cy5 intensities of a given genomic segment
was > 0.6 or <−0.8, respectively. As reference DNA, we
used commercially available human Promega female
DNA (Promega, Madison, WI, USA).
Breakpoint Sequencing Analysis
To assess the microdeletion breakpoints, specific pri-
mers (forward: 5'- ACTCTGAGGACAAAGCAGCGGA
-3'; reverse: 5'-GTGCCACCAAGCCCGGCTAA -3')
were designed in order to amplify the breakpoint region
of the BRCA1 rearrangement (microdeletion involving
the same exons described by [20]. A 450 bp fragment
was detected only in the sample with the microdeletion,
and absent in the normal controls. The 450 bp fragment
was purified from the gel using the Gel Band Purifica-
tion Kit (Illustra, GE Healthcare UK limited, Bucking-
hamshire, United Kingdom) and sequenced (forward and
reverse) using the Big Dye V3.1 Terminator Kit (Applied
Biosystems, Forster City, CA, USA) on an automated se-
quencer ABI Prism 310 Genetic Analyser (Applied Bio-
Systems,) according to the manufacturer’s instructions.
We performed an in silico analysis of the genomic
sequences surrounding the breakpoints using the
RepeatMasker program (http://www.repeatmasker.org/)
that screens DNA sequences for interspersed repeats
and low complexity DNA sequences.
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